Ronald S. Diamond, Chairman and CEO, Diamond Wealth, based in Chicago, IL; Chicago Chair, TIGER 21; former Director, Stanford University Global Family Office Initiative

Mr. Diamond is the former Director of the Stanford University Global Family Office Initiative and served as former Chairman of the Advisory Board at Stanford University for the Disruptive Technology and Digital Cities Program. In addition, Mr. Diamond guest lectures at Stanford’s Graduate Business School, Graduate Engineering School, and the Entrepreneur program. He serves on the Advisory Board of 10 privately held companies and acts as Chairman for 4 of them. Mr. Diamond is also the Chair of two TIGER 21 chapters in Chicago.

A frequent speaker at Family Office and Alternative Investment Conferences, Mr. Diamond has spoken at over 100 conferences across the globe. Mr. Diamond is also the Founder of Family Office World — (www.familyofficeworldpodcast.com) a podcast whose mission is to educate the market about Family Offices.

Earlier in his career, Mr. Diamond founded Pinnacle Capital — a $250 million hedge fund that outperformed the S&P index 10 out of 10 years — before ultimately selling his company to an international investment firm. Previously, Mr. Diamond served as a Senior Managing Director at Bear Stearns. He began his career as an analyst at Drexel Burnham Lambert.

Deeply committed to giving back, Mr. Diamond is an active philanthropist and civic leader. He is Chairman of the Advisory Board for the World Peace Initiative launched at Stanford University. He also serves as the Chairman of the Advisory Board of JSC and currently sits on the Board at the JCC and JUF.

Mr. Diamond studied at Northwestern University, graduating Magna Cum Laude and earning his degree in Economics.

Angus McLachlan, PhD, Co-Founder and CEO, Liberate Medical, based in Crestwood, KY

Dr. Angus McLachlan co-founded Liberate Medical and has served as a member of its board of directors and its Chief Executive Officer since 2013. From 2014 to 2016, he also served as the Director for Device Integration and Strategy for Revon Systems. Dr. McLachlan completed his doctoral research on Liberate Medical’s proprietary electrical muscle stimulation technology and was responsible for the initial product development of VentFree and SecondBreath, which led to the technology being spun out of Apellis Pharmaceuticals. He is co-inventor on all of Liberate Medical’s patents and has authored several important publications in the field of abdominal functional electrical stimulation. Dr. McLachlan received his M.Eng. in Mechanical Engineering and his Ph.D. in Biomedical Engineering from the University of Glasgow, Scotland.

Meet Dr. McLaughlin and Liberate Medical by logging in to Cavendish IQ.

Theresa Deisher, PhD, President and CEO, AVM Biotechnology, based in Seattle, Wash.

To combat disease, we are armed with a special weapon: AVM0703. AVM0703 is a purer and loaded formulation of dexamethasone which has been used at lower doses since 1958 for other purposes. Our supra-pharmacologic dose has a novel mechanism of action (MOA) to mobilize the body’s own natural supercharged immune cells that are ten times more activated than ordinary immune cells.

AVM0703 has activity in mouse models even against aggressive, impossible to cure cancer models. Preclinical studies show dramatic tumor reduction with supercharged NKT (Natural Killer T Cells) which are tenfold more efficient in killing tumors than normal NKT cells. Recently the UK has adopted 10 daily doses of 0.6 mg/kg dexamethasone (total 6 mg/kg) as standard of care for severe COVID-19 patients. Dexamethasone is the only drug that has been shown to reduce COVID-19 mortality (by 30%). Our purer and loaded AVM0703 could safely deliver the total 6 mg/kg dose as a single acute 1 hour IV infusion. Based on preclinical cancers models and compassionate use in cancer and GvHD patients, we hypothesize that AVM0703 could reduce days in ICU from 10+ days down to 2-3 days.

Our passion is to deliver drugs that work rapidly and that are safe, effective, and affordable, to treat serious worldwide illness like cancer, autoimmunity, and life-altering infectious disease. We will serve overlooked populations; pediatric and adolescent patients, frail and elderly, and the poorer amongst us. We develop products that improve outcomes without additional suffering because we believe that side effects from treatments of cancers or infections should never be worse than the diseases themselves.

Meet Dr. Deisher and AVM by logging in to Cavendish IQ.